Legend Biotech's Pivotal Transition — CARVYKTI Momentum Meets a New Leadership Era!
Legend Biotech reported second-quarter 2026 results showing continued commercial and clinical growth alongside a leadership transition. Following...
104 Views
LEGN: 2Q26 Call Takeaways; 2026 Profitability on Track; Next up on LB2501 (In Vivo CAR-T) Updates
2Q26 profitability on track, with Carvykti sales up 50% YoY and operating margin of 15%; LEGN 2H26 key catalysts: continued QoQ Carvykti growth +...
108 Views
China Healthcare Weekly Wrap (21-25 Sep)
We highlight 1) key studies to watch for upcoming October's ESMO updates, 2) deal flows Innocare/Lilly, BoomRay/Novartis, Earendil Labs...
95 Views
Legend Biotech's In Vivo CAR-T Pipeline: Could BCMA And GPRC5D Reset The Story?
Legend Biotech reported its first quarter of 2026 financial and operational results marked by continued commercial expansion of its lead product,...
113 Views
Legend Biotech Corp (LEGN US): Synthetic Expert Call Transcript (29 Jun 2026)
Efficacy Supremacy but Operational Friction: Carvykti’s 0.26 hazard ratio from the CARTITUDE-4 trial establishes it as the clinical gold standard...
117 Views